Atezolizumab associated with Bevacizumab in non-clear cell renal cell carcinoma and clear cell renal cell carcinoma with sarcomatoid differentiation
Non-clear cell renal cell carcinoma ( NccRCC ) and clear cell renal cell carcinoma with sarcomatoid differentiation ( sccRCC ) have historically been underrepresented in clinical trials.
Even with targeted therapy, most patients have inferior survival compared to clear cell renal cell carcinoma.
The combination of Atezolizumab ( Tecentriq ) and Bevacizumab ( Avastin ) has demonstrated safety and efficacy in clear cell renal cell carcinoma.
In this multicenter, phase II, open-label, single arm trial researchers have evaluated the efficacy of Atezolizumab and Bevacizumab in patients with nccRCC and sccRCC with more than 20% sarcomatoid differentiation.
Eligible patients had an ECOG performance status of 0-2 and may have received prior therapy. Prior PD-1/PD-L1 therapy was not allowed.
Patients underwent a mandatory baseline biopsy and subsequently received Atezolizumab 120 mg and Bevacizumab 15 mg/kg intravenously every 3 weeks.
Patients remained on therapy until radiographic progression, unacceptable adverse events, or withdrawal.
The primary end point was overall response rate ( ORR ) as determined by RECIST version 1.1.
65 patients were enrolled of whom 52 had greater than or to 1 response assessment and were included in this analysis.
36 patients had nccRCC ( papillary n=14, chromophobe n=8, unclassified RCC n=3, collecting duct n=3, translocation n=3, other n=5 ), and 16 patients had sccRCC.
17 patients received prior systemic therapy, 16 of whom had nccRCC.
The ORR was 31% in the overall cohort.
10 patients ( 19% ) developed grade 3 treatment-related adverse events, half of which were immune-related.
There were no grade 4-5 adverse events.
In this study, researchers have shown that therapy with Atezolizumab and Bevacizumab was safe and demonstrated anti-tumor activity in nccRCC and sccRCC. ( Xagena )
Source: Genitourinary Cancers Symposium, 2019
Acid reflux drugs that are sometimes recommended to ease stomach problems during cancer treatment may have an unintended side effect:...
The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within...
UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million...
European Commission has approved Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia
The European Commission has approved Venclyxto ( Venetoclax ) in combination with Gazyvaro ( Obinutuzumab ) for the treatment of...
Ibrutinib treatment for first-line and relapsed / refractory chronic lymphocytic leukemia: final analysis of PCYC-1102 study
The safety and efficacy of Ibrutinib ( Imbruvica ), a once-daily Bruton's tyrosine kinase inhibitor, in chronic lymphocytic leukemia...
Advanced renal cell carcinoma: outcomes based on age in the phase III METEOR trial of Cabozantinib versus Everolimus
Cabozantinib ( Cabometyx ) has improved progression-free survival ( PFS ), overall survival ( OS ) and objective response rate...
FDA: Opdivo plus Yervoy as first-line treatment of patients with metastatic non-small cell lung cancer with PD-L1 expression greater than or equal to 1%
Opdivo ( Nivolumab ) 3 mg/kg plus Yervoy ( Ipilimumab ) 1 mg/kg ( injections for intravenous use ) was...
Metastatic non-small cell lung cancer: Tecentriq has demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy - FDA has approved
The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) as a first-line treatment for...
Rubraca as monotherapy treatment for patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer, treated with androgen receptor-directed therapy and a taxane-based chemotherapy
The FDA ( U.S. Food and Drug Administration ) has approved Rubraca ( Rucaparib ) tablets for the treatment...